<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Skin and Venereal Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Skin and Venereal Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский журнал кожных и венерических болезней</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1560-9588</issn><issn publication-format="electronic">2412-9097</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">677350</article-id><article-id pub-id-type="doi">10.17816/dv677350</article-id><article-id pub-id-type="edn">JQMJHK</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DERMATOLOGY</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДЕРМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Filaggrin: a key to understanding and treating atopic dermatitis</article-title><trans-title-group xml:lang="ru"><trans-title>Филаггрин: ключ к пониманию и лечению атопического дерматита</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7968-7663</contrib-id><contrib-id contrib-id-type="spin">3785-7859</contrib-id><name-alternatives><name xml:lang="en"><surname>Snarskaya</surname><given-names>Elena S.</given-names></name><name xml:lang="ru"><surname>Снарская</surname><given-names>Елена Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>snarskaya-doc@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-0156-7668</contrib-id><name-alternatives><name xml:lang="en"><surname>Daduns</surname><given-names>Diana</given-names></name><name xml:lang="ru"><surname>Дадунц</surname><given-names>Диана</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>dadunsdiana2002@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7284-9113</contrib-id><contrib-id contrib-id-type="spin">6012-7555</contrib-id><name-alternatives><name xml:lang="en"><surname>Bratkovskaya</surname><given-names>Anna V.</given-names></name><name xml:lang="ru"><surname>Братковская</surname><given-names>Анна Вадимовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>annabratk24@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">The First Sechenov Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-09-22" publication-format="electronic"><day>22</day><month>09</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-11-01" publication-format="electronic"><day>01</day><month>11</month><year>2025</year></pub-date><volume>28</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>460</fpage><lpage>469</lpage><history><date date-type="received" iso-8601-date="2025-03-20"><day>20</day><month>03</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-06-02"><day>02</day><month>06</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-Вектор</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2028-11-01"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://rjsvd.com/1560-9588/article/view/677350">https://rjsvd.com/1560-9588/article/view/677350</self-uri><abstract xml:lang="en"><p>Atopic dermatitis is a chronic inflammatory genetically determined skin disease characterized by high prevalence and a significant negative impact on patients’ quality of life. Impairment of the skin barrier in atopic dermatitis is closely associated with filaggrin deficiency—a key structural protein of the epidermis. Loss-of-function mutations in the FLG gene are a major genetic risk factor for atopic dermatitis, significantly worsening its course and prognosis.</p> <p>Currently, active research is underway to develop effective methods for restoring filaggrin deficiency, which represents a promising approach in the therapy of atopic dermatitis. This article provides a systematic scientific data analysis in the PubMed, Google Scholar, and ClinicalTrials.gov databases to identify modern approaches to restoring the skin barrier in atopic dermatitis by targeting filaggrin and its metabolism. The following promising strategies for targeting filaggrin have been identified: direct replacement therapy with recombinant forms of filaggrin, the use of metabolites (L-histidine, cis-urocanic acid), plant extracts, and mechanical stimulation methods. These approaches demonstrate the potential to improve skin barrier function and reduce inflammation; however, further studies are needed to confirm their clinical efficacy and clarify mechanisms of action.</p> <p>Modern strategies for correcting filaggrin deficiency hold significant therapeutic potential for atopic dermatitis but require further research, including at the molecular and clinical levels, to enable their integration into clinical practice.</p></abstract><trans-abstract xml:lang="ru"><p>Атопический дерматит ― хроническое воспалительное, генетически детерминированное заболевание кожи с высокой распространённостью, значительным негативным влиянием на качество жизни пациентов. Нарушение кожного барьера при атопическом дерматите тесно связано с дефицитом филаггрина ― ключевого структурного белка эпидермиса. Мутации гена <italic>FLG</italic>, приводящие к потере функции белка, являются важнейшим генетическим фактором риска атопического дерматита, существенно утяжеляющим его течение и прогноз.</p> <p>В настоящее время ведутся активные исследования, направленные на разработку эффективных методов восстановления дефицита филаггрина, что представляет собой перспективное направление терапии атопического дерматита. В статье проведён систематический анализ литературы с целью поиска современных подходов к восстановлению кожного барьера при атопическом дерматите путём воздействия на филаггрин и его метаболизм (поиск источников литературы осуществлялся в базах данных PubMed, Google Scholar, ClinicalTrials.Gov). Выделены перспективные стратегии воздействия на филаггрин: прямая заместительная терапия с использованием рекомбинантных форм филаггрина, применение метаболитов (L-гистидин, цис-урокановая кислота), растительных экстрактов, механических методов стимуляции. Представленные подходы демонстрируют способность улучшать барьерные функции кожи и ослаблять воспалительные процессы, однако нуждаются в подтверждении клинической эффективности и уточнении механизмов действия.</p> <p>Современные стратегии коррекции дефицита филаггрина обладают высоким потенциалом для терапии атопического дерматита, но требуют дальнейших исследований, в том числе на молекулярном и клиническом уровнях, с целью внедрения в клиническую практику.</p></trans-abstract><kwd-group xml:lang="en"><kwd>atopic dermatitis</kwd><kwd>filaggrin</kwd><kwd>skin barrier</kwd><kwd>recombinant filaggrin</kwd><kwd>natural moisturizing factor</kwd><kwd>FLG mutations</kwd><kwd>filaggrin synthesis modulators</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>атопический дерматит</kwd><kwd>филаггрин</kwd><kwd>кожный барьер</kwd><kwd>рекомбинантный филаггрин</kwd><kwd>натуральный увлажняющий фактор</kwd><kwd>мутации FLG</kwd><kwd>модуляторы синтеза филаггрина</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Atopic dermatitis. Clinical recommendations. Russian Society of Dermatovenerologists and Cosmetologists, Russian Association of Allergologists and Clinical Immunologists, Union of Pediatricians of Russia; 2021. 81 p. (In Russ.) Available at: https://www.rodv.ru/upload/iblock/8e8/8e8aa942015890c46779cc7507442707.pdf?ysclid=mc2bjq3l5m675594893 Accessed: April 15, 2025.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Silverberg JI, Anderson P, Cappelleri JC, et al. Burden of mild and moderate atopic dermatitis in adults: Results from a real-world study in the United States. Arch Dermatol Res. 2025;317(1):556. doi: 10.1007/s00403-025-03910-y</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405(10478):583–596. doi: 10.1016/S0140-6736(24)02519-4</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Drislane C, Irvine AD. The role of filaggrin in atopic dermatitis and allergic disease. Ann Allergy Asthma Immunol. 2020;124(1):36–43. doi: 10.1016/j.anai.2019.10.008</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Williams HC, Simpson EL, Langan SM, et al. Achieving long-term control in atopic dermatitis: Emerging concepts, definitions, flares and therapy. J Allergy Clin Immunol Pract. 2025;S2213-2198(25)00184-9. doi: 10.1016/j.jaip.2025.02.013</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Marshall LL. Atopic dermatitis in adults: Focus on topical therapy. Sr Care Pharm. 2025;40(3):123–134. doi: 10.4140/TCP.n.2025.123</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Dębińska A. New treatments for atopic dermatitis targeting skin barrier repair via the regulation of FLG expression. J Clin Med. 2021;10(11):2506. doi: 10.3390/jcm10112506</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Zhu J, Zhong X, Liao H, et al. A novel recombinant human filaggrin segment (rhFLA-10) alleviated a skin lesion of atopic dermatitis. Bioengineering (Basel). 2024;11(5):426. doi: 10.3390/bioengineering11050426</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Stout TE, McFarland T, Mitchell JC, et al. Recombinant filaggrin is internalized and processed to correct filaggrin deficiency. J Investig Dermatol. 2014;134(2):423–429. doi: 10.1038/jid.2013.284</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Li L, Liu Y, Chang R, et al. Dermal injection of recombinant filaggrin-2 ameliorates UVB-induced epidermal barrier dysfunction and photoaging. Antioxidants. 2024;13(8):1002. doi: 10.3390/antiox13081002</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Stefanovic N, Irvine AD. Filaggrin and beyond. Ann Allergy Asthma Immunol. 2024;132(2):187–195. doi: 10.1016/j.anai.2023.09.009</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Hoober JK, Eggink LL. The discovery and function of filaggrin. Int J Mol Sci. 2022;23(3):1455. doi: 10.3390/ijms23031455</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Peltonen J, Pylkkänen L, Jansén C, et al. Three randomised phase I/IIa trials of 5% cis-Urocanic acid emulsion cream in healthy adult subjects and in patients with atopic dermatitis. Acta Dermatol Venereol. 2014;94(4):415–420. doi: 10.2340/00015555-1735</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Tan SP, Brown SB, Griffiths C, et al. Feeding filaggrin: Effects of L-histidine supplementation in atopic dermatitis. Clin Cosmet Investig Dermatol. 2017;10:403–411. doi: 10.2147/CCID.S146760</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Gibbs NK. The efcacy and safety of L-histidine supplementation in adults and infants with atopic dermatitis (eczema). In: Proceedings of the 10 ICAAS amino acid assessment workshop. Tokyo; 2019. P. 25–26.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Sakuraba K, Kojima Y, Terahara T, et al. Non-invasive microneedle application increases ceramide and natural moisturizing factors in a reconstructed human skin model. Biol Pharm Bull. 2023;46(9):b23-00294. doi: 10.1248/bpb.b23-00294</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Lu Y, Zhang W, Zhou L, et al. The moisturizing effect of Capparis spinosa fruit extract targeting filaggrin synthesis and degradation. J Cosmet Dermatol. 2023;22(2):651–660. doi: 10.1111/jocd.15461</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Tsukui K, Kakiuchi T, Suzuki M, et al. The ion balance of Shotokuseki extract promotes filaggrin fragmentation and increases amino acid production and pyrrolidone carboxylic acid content in three-dimensional cultured human epidermis. Nat Prod Bioprospect. 2022;12(1):37. doi: 10.1007/s13659-022-00353-0</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Majewski G, Craw J, Falla T. Accelerated barrier repair in human skin explants induced with a plant-derived PPAR-α activating complex via cooperative interactions. Clin Cosmet Investig Dermatol. 2021;14:1271–1293. doi: 10.2147/CCID.S325967</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Choi HK, Cho YH, Lee EO, et al. Phytosphingosine enhances moisture level in human skin barrier through stimulation of the filaggrin biosynthesis and degradation leading to NMF formation. Arch Dermatol Res. 2017;309(10):795–803. doi: 10.1007/s00403-017-1782-8</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Takeda S, Miyasaka K, Shrestha S, et al. Lycoperoside H, a tomato seed saponin, improves epidermal dehydration by increasing ceramide in the stratum corneum and steroidal anti-inflammatory effect. Molecules. 2021;26(19):5860. doi: 10.3390/molecules26195860</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Ahn SH, Shin S, Do Y, et al. Topical application of Galgeunhwanggeumhwangryeon-Tang recovers skin-lipid barrier and ameliorates inflammation via filaggrin-thymic stromal lymphopoietin-interleukin 4 pathway. Medicina (Kaunas). 2021;57(12):1387. doi: 10.3390/medicina57121387</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Lv WJ, Huang JY, Li SP, et al. Portulaca oleracea L. extracts alleviate 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice. Front Nutr. 2022;9:986943. doi: 10.3389/fnut.2022.986943</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Granato L. Modulator from fractions of vegetable unsaponifiables. Personal Care. 2012. P. 69–72.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Masalskiy SS, Smolkin YuS, Smolkina OYu. Clinical and hardware evaluation of moisturizing properties and tolerability of a emollient cream with filagrinol (Admera) in atopic dermatitis in children. Allergol Immunol Paediatric. 2023;(2):16–32. doi: 10.53529/2500-1175-2023-2-16-32</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Snarskaya ES, Bratkovskaya A V. Novel filagrinol-containing emollient. Vestnik dermatologii i venerologii. 2022;98(5):65–89. doi: 10.25208/vdv1342 EDN: GBGMIW</mixed-citation></ref></ref-list></back></article>
